——The 20th anniversary of Chengdu biopurify pharmaceuticals Ltd
Preface
In the past 20 years, it is only a flash in the long river of history, but it is a long journey enough to engrave the original intention and measure the dream for a traditional Chinese medicine enterprise that focuses on the essence of Materia Medica.
From 2006 to 2026, it started from Shudi to become a laboratory and pharmaceutical enterprise in more than 60 countries around the world; From a small team with ideals to National Institutes for Food and Drug Control (NIFDC)、European Pharmacopoeia、United States Pharmacopeia A trusted partner. “Concentrate on the essence of Materia Medica and benefit all living beings”(focus on herbal essence, let it benefit human beings) has been on the journey of modernization of traditional Chinese medicine and research and development of natural products for 20 years.
1、 The original heart is like a rock: twenty years from a grass to a storehouse
Biopurify was founded in Chengdu in 2006. At that time, the domestic market for traditional Chinese medicine reference substances was still in its infancy, and many key traditional Chinese medicine ingredients were imported for a long time, with high prices and unstable supply. “Chinese people should be world-class when they are used as reference materials of traditional Chinese Medicine”。
Over the past 20 years, we have turned this idea into reality step by step:
·2018 Via ISO9001 quality management system certification
·2019 Awarded as a high-tech enterprise; In April of the same year, the industrial production process of ginsenoside compound K made a breakthrough
·2020 Passed the certification of intellectual property management system
·2021 Via CNAs national accredited laboratory certification; In March, the industrial process of sarsasapogenin made another breakthrough;
·In 2023, the company was rated as a specialized, special and new enterprise
·2023 The 19th Chinese medicine globalization alliance conference was held in Chengdu, and the company participated in it
·2025 Launched the drug likeness database of natural products and sponsored the 15th National Natural Organic Chemistry Academic Conference
·2026 Launch the new year special "buy compounds to give disease, targets and drug likeness data" to enable scientific research with data
From a grass to aMorethan4000 compoundsThe chemical composition Library of traditional Chinese medicine has been developed from a laboratory to a compliant The R & D platform and pilot plant required by GMP and FDA have been paved by sweat, patents and certification in the past 20 years.
2、 Talent oriented: a group of colleagues who "understand traditional Chinese medicine and research and development"
The thickness of twenty years, in the final analysis, is the thickness of people.
·Xieqilin, general manager——Senior engineer, licensed pharmacist, 26 years of experience in new drug research and development and quality management, has presided over many new drug applications, has FDA factory quality management experience, and is biopurfy's "fixed star".
·Xiehaifeng, deputy general manager——He is a senior engineer, a professional and master tutor of China Pharmaceutical University and Shenyang Pharmaceutical University. He has a deep accumulation in the field of natural product separation and experienced every purification curve of the company from scratch.
·Huyunling, deputy general manager——Licensed pharmacists, who coordinate the company's pharmaceutical compliance and production management, are the guardians of the bottom line of quality.
·Professor zhangchaofeng——He is a strategic partner, Professor of China Pharmaceutical University and vice president of the College of traditional Chinese medicine, specializing in the research of active ingredients of traditional Chinese medicine regulating the process of organ fibrosis, and is a model of in-depth collaboration between industry, University and research.
In the past 20 years, from the visit and guidance of academician Peigang (2014) and academician yaoxinsheng (2018) of Tongji University, to the investigation and visit of Professor wangzhengtao of Shanghai University of traditional Chinese medicine and Professor Zhang yongxun of China Medical University in Taiwan (2023), every visiting scholar has injected new wisdom into this small and excellent team.
3、 Scientific research achievements: from compound library to candidate new drugs
The accumulation of research and development in the past two decades does not remain at the level of "making reference materials". Biopurify has already turned every grass and molecule into a real hope to fight against stubborn diseases:
▎ anti pulmonary fibrosis series
The five-year survival rate of pulmonary fibrosis is only 20% – 50%, and the mortality rate is even higher than that of a variety of cancers. Relying on the resource library of more than 4000 active monomers of traditional Chinese medicine, we screened and locked several effective active parts and monomers:
·PRF1837——The most potential candidate compound for anti pulmonary fibrosis has been transferred to a pharmaceutical factory in Guangxi for phase I preclinical research
·Natural products ARJ——The research direction of a new generation of anti pulmonary fibrosis, which was approved in 2024, is promoting structural modification and Derivative Development
·In 2018, he was supported by the National Natural Science Foundation of China (Project No. 81773982）, explore Siraitia grosvenorii based onAMPK-TLR4 The material basis of signal, specimen and treatment of pulmonary fibrosis
▎ ischemic stroke
Prf2201 series compounds——The effective monomer derived from Valeriana officinalis showed significantly improved cerebral ischemia activity after derivatization by the team. The patent has been applied and international patent applications have been prepared.
▎ industrialization of rare ginsenosides
After years of deep cultivation, we have conqueredCK、Rh1、Rh2、Rg3、Rg5 .
▎ intellectual property
Over the past 20 years, the company has applied forDozens of patents at home and abroadIt covers the preparation of Mogroside IV, Rhaponticin anti pulmonary fibrosis, separation and purification of ingenol, effective parts of ginseng stems and leaves, anti haze traditional Chinese medicine composition and other directions, and builds a solid core barrier.
4、 Going global: trust between customers in 60 countries and three Pharmacopoeias
In the past 20 years, biopurify's products haveMore than 60 countries and regions：
·YesNational Institutes for Food and Drug Control (NIFDC)traditional Chinese medicineImportant suppliers of reference materials and raw materials
·YesEuropean Pharmacopoeia（EP）WithUnited States Pharmacopeia（USP）Major suppliers of certified reference materials for traditional Chinese medicine ingredients
·Thanks to excellent products and services,United States Pharmacopeia specially awarded honorary certificates to the company
.
5、 Smart computing drive: North America "Silicon based brain" of AI drug design center
In the past 20 years, biopurify has been carving in the world of natural molecules with a carving knife; In the next 20 years, we will have another sharp weapon in our hands——artificial intelligence。
In order to grasp the intelligent wave of global drug research and development, biopurifySet up in North America AI drug design center, constructedIntegration from computational design to experimental verification AI drug discovery platform, deep integration of artificial intelligence and computational chemistry, through“Target analysis molecular generation structure prediction kinetic simulation drug likeness evaluation”.
It used to take months to screen and optimize the lead compounds, but now it can be completed in a few days.
The platform has been successfully applied to innovative drug design in multiple therapeutic fields, coveringPeptide drugsWithNatural product drugs, withMillion level compound libraryLarge scale virtual screening capability. By adding With the deep combination of AI model and molecular simulation, we have formed unique technical advantages in the following directions:
·Multi target collaborative design——Breaking through the limitation of single target and coping with complex diseases
·Oral delivery of peptide drugs——Overcoming the bottleneck of peptide drug likeness
·Structural modification of natural products——AI enables "old medicine to regenerate"
·Peptide cosmetic raw materials——Multi target sequence design and activity optimization
▎ hard computing power: escort of enterprise GPU platform
Supporting all this is the high-performance self built by the center GPU computing platform - all based on Dell high performance computing platformBuild:
|
Configuration item |
specifications |
|
Core node |
Dell precision enterprise workstation |
|
Computational extension |
Multiple high-performance GPU computing node |
|
Accelerator card |
7 flagship Professional Computing cards |
|
GPU total video memory |
Near 300 GB |
|
system memory |
Super 700 GB |
|
Aggregate computing power |
Hundreds TFLOPS |
|
High speed storage |
240 TB+ |
With the stability of enterprise class hardware, guaranteeLarge scale molecular dynamics simulation, virtual screening and AI model training / reasoningMulti task parallel of - provides a solid computing base for the whole process of drug discovery.
"Traditional herbal wisdom" × "modern AI computing power" -- this isBiopurifyTwenty years of inheritance alsoBiopurifyFuture oriented answers.
6、 Facing the future: innovate in inheritance and travel far in innovation
Looking back at the node of 20 years, it is accumulation; Looking forward to the future is going forward.
New generation R & D platformThe key words of are becoming wider:
·Continue to promote the structural modification and biomimetic synthesis of natural products by enzymatic method and biogenic Technology
·Construction complies with Cnas/iso/iec17025/cma and other internationally certified quality standard research and testing platforms (CNAs and iso9001 Passed)
·Starting from the compound library, screening prescriptions, developing health food, plant beverage, functional daily chemical products, and expanding the territory of the large health industry
·The drug likeness database of natural products released in 2025 will continue to iterate into the industry's R & D infrastructure
·North America
; Twenty years later, we are guarding a forest connecting traditional herbal medicine and modern medicine, connecting Oriental wisdom and the global frontier, and connecting wet experiment and computational brain.
Conclusion: to the next 20 years
Over the past 20 years, biopurify has gained more than certificates, patents and orders.
What we gain is——
In constant awe of the word "Materia Medica",
It is consistent with the word "R & D",
Commitment to "customers" for decades.
To every partner in the industry for 20 years, and to every customer and partner who is about to meet us:
In the next 20 years,BiopurifyWith herbal medicine as the root and intelligent calculation as the wing, I will go to the sea of stars with you.
We look forward to working with you to create a better future!
